ENA 713

Known as: ENA713, ENA-713, ENA 713, SDZ 
 

Topic mentions per year

Topic mentions per year

1993-2005
02419932005

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Oral ENA713 (0.5, 1.5 and 4.5 mg/kg), an acetylcholinesterase inhibitor (AChEI), dose-dependently enhanced extracellular… (More)
Is this relevant?
1999
1999
  Rationale: The disruption of working memory in the delayed non-matching to position (DNMTP) task by the muscarinic antagonist… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
1999
1999
The effects of oral administration of the centrally acting acetylcholinesterase (AChE) inhibitors, donepezil hydrochloride… (More)
Is this relevant?
1999
1999
This study sought to examine the feasibility of prolonged assessment of acetylcholinesterase (AChE) activity in the cerebrospinal… (More)
Is this relevant?
1998
1998
Purpose. SDZ ENA 713 (rivastigmine) is an acetylcholinesterase inhibitor intended for therapeutic use in Alzheimer's disease. The… (More)
Is this relevant?
1998
1998
Focal ischemic brain damage and diffuse brain swelling occur in severe cases of traumatic head injury. Ischemia decreases brain… (More)
Is this relevant?
1996
1996
SDZ ENA 713 (ENA 713) is an acetylcholinesterase inhibitor being developed as a potential treatment for Alzheimer's disease (AD… (More)
Is this relevant?
1995
1995
We examined by morphological methodology the effect of (S)-N-ethyl-3-[(1-dimethyl-amino)ethyl]-N-methyl-phenylcarbamate… (More)
  • figure 1
  • table I
  • figure 2
  • table II
Is this relevant?
1994
1994
The effects of pre-treatment with ENA-713, an acetylcholinesterase (AChE) inhibitor, on changes in pre- and postsynaptic… (More)
  • figure 2
  • figure 1
  • table I
  • figure 3
  • figure 4
Is this relevant?
1993
1993
The effects of a new acetylcholinesterase inhibitor, ENA-713, on ischemia-induced changes in acetylcholine, monoamines, and their… (More)
Is this relevant?